MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on July 28, 2005; DOI: 10.1124/mol.105.017335

0026-895X/05/6804-956-958$20.00
Mol Pharmacol 68:956-958, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.105.017335v1
68/4/956    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burris, T. P.
Right arrow Articles by Krishnan, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burris, T. P.
Right arrow Articles by Krishnan, V.
PERSPECTIVE

Estrogen: A Mitochrondrial Energizer That Keeps on Going

Thomas P. Burris, and Venkatesh Krishnan

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana (T.P.B., V.K.); and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana (T.P.B.)

Estrogens demonstrate vasoprotective activity in many experimental models. These effects have been attributed to beneficial activity of these steroids on lipid metabolism as well as direct effects on the vasculature via modulation of nitric-oxide synthase and phosphatidylinositol-3 kinase/Akt signaling pathways. In this issue of Molecular Pharmacology, Stirone et al. (p. 959) present evidence suggesting that 17{beta}-estradiol may also exert vasoprotective effects in cerebral blood vessels via stimulation of mitochondrial energy production capacity and inhibition of reactive oxygen species production. These data indicate not only yet another potential mechanism underlying the vasoprotective effects of estrogens but also that the estrogen receptor may coordinate gene expression in both the nuclear and mitochondrial genomes.

Received July 26, 2005; accepted July 28, 2005

Address correspondence to: Dr. Thomas P. Burris, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: burris{at}lilly.com




This article has been cited by other articles:


Home page
 Mol. Interv.Home page
A Career in Pharmacology: In Search of Beauty and Joy
Mol. Interv., August 1, 2007; 7(4): 183 - 189.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Wang, J. A. Dykens, E. Perez, R. Liu, S. Yang, D. F. Covey, and J. W. Simpkins
Neuroprotective Effects of 17beta-Estradiol and Nonfeminizing Estrogens against H2O2 Toxicity in Human Neuroblastoma SK-N-SH Cells
Mol. Pharmacol., July 1, 2006; 70(1): 395 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
S. P. Duckles, D. N. Krause, C. Stirone, and V. Procaccio
Estrogen and mitochondria: a new paradigm for vascular protection?
Mol. Interv., February 1, 2006; 6(1): 26 - 35.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics